Status:
COMPLETED
Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
Wren Laboratories LLC
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
To study if a targeted gene expression profile of RNA, similar to the NETest, can be isolated from the peripheral blood of patients with melanoma, to identify active disease, provide an assessment of ...
Detailed Description
* Evaluate the diagnostic efficacy of a circulating melanoma gene signature in pathologically verified Stage III melanoma at diagnosis (biopsy-proven lymph node positive) and compare this to LDH as a ...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Primary melanoma \> 1 mm in Breslow depth
- Stage III or IV disease as determined either by sentinel node biopsy, biopsy of clinically enlarged lymph nodes, and/or imaging. If stage IV, must have tissue biopsy confirming presence of stage IV melanoma
Exclusion
- Pregnant patients
- Contraindication to contrasted imaging (due to allergy or renal insufficiency)
- Serum PCV \<30%
Key Trial Info
Start Date :
October 3 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 27 2023
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT03267381
Start Date
October 3 2017
End Date
September 27 2023
Last Update
December 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232